Industry leaders highlighted the pharmaceutical sector’s role in advancing research, innovation, early screening, and multi-stakeholder collaboration
The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth
The MAST trial is designed to test whether a single dose of pre-emptive, orally administered EBX-102-02 can protect and restore microbial diversity during transplantation
Phase I EPRAD study of DT-9081 demonstrated a favorable safety profile
The hospitals house over 25 super-speciality centres and Centres of Excellence in Cardiology, Neurology, Oncology, Paediatrics, Orthopaedics, ENT, Obstetrics and Gynaecology, General Surgery, Internal Medicine, Critical Care, and Chronic Disease Management
The study showed a 76% complete response (CR) rate at 12 months, rising to 95% at any time for high-risk NMIBC patients
Enhertu recently received Breakthrough Therapy Designation, accelerating development and review for this critical patient population
Evogene said ChemPass AI was significantly expanded during 2025 through internal development and collaborations with Google Cloud
The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations
It is also approved for?AIDS-related Kaposi sarcoma?after failure of highly active antiretroviral therapy, as well as for HIV-negative adult patients with Kaposi sarcoma
Subscribe To Our Newsletter & Stay Updated
